BioPharma Dive November 30, 2022
The Dublin-headquartered company confirmed it is “highly preliminary” talks with Amgen, J&J and Sanofi.
Horizon Therapeutics, a Dublin-based maker of drugs for rare and inflammatory diseases, has drawn acquisition interest from several large pharmaceutical companies.
On Tuesday, Horizon confirmed it is in “highly preliminary” discussions with Amgen, Johnson & Johnson and Sanofi about a potential takeover. The company cautioned no offer may be forthcoming and an acquisition might not materialize. The Wall Street Journal first reported on the discussions.
Shares in Horizon, which were worth about $79 apiece Tuesday, rose by 31% in after hours trading on the Nasdaq stock exchange. Prior to that spike, the company was valued at just under $18 billion.
Horizon sells a handful of approved...
Today's Sponsors
Today's Sponsor